New combo aims to stop liver cancer recurrence in High-Risk patients
NCT ID NCT07337460
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of Icaritin soft capsules and a liver-directed chemotherapy infusion (mFOLFOX) can prevent hepatocellular carcinoma from coming back after surgery in patients with high-risk features. About 30 participants will receive the treatment for up to a year. The study tracks how long patients stay cancer-free and their overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Icaritin soft capsules and mFOLFOX chemotherapy (oxaliplatin, leucovorin calcium, 5-fluorouracil)
What this could lead to
If it works, this combination could help prevent liver cancer from coming back after surgery in patients at high risk of recurrence.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group, so results may not be conclusive. The chemotherapy and Icaritin can cause side effects like nausea, fatigue, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Medical College of Yangzhou University
RECRUITINGYangzhou, Jiangsu, 225001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••